PT Diastika Biotekindo Tbk (IDX:CHEK)

Revenue by Segment

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Clinical Diagnostics	141.86B	116.98B	108.15B	100.67B
Clinical Diagnostics Growth	21.26%	8.17%	7.43%	-
Life Science	59.45B	37.81B	20.95B	16.80B
Life Science Growth	57.24%	80.46%	24.68%	-
Total	201.31B	154.79B	129.10B	117.47B
Total Growth	30.05%	19.90%	9.90%	-

Revenue by Geography

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Indonesia	201.31B	154.79B	129.10B	117.47B
Indonesia Growth	30.05%	19.90%	9.90%	-
Total	201.31B	154.79B	129.10B	117.47B
Total Growth	30.05%	19.90%	9.90%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 20, 2026

Data Sources Report a data error